RCS - MaxCyte, Inc. - HC Wainright & Co Virtual Conference Presentation
10/09/2020 07:00
For best results when printing this announcement, please click on link below: http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200910:nRSJ5403Ya RNS Number : 5403Y MaxCyte, Inc. 10 September 2020 MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference GAITHERSBURG, MD, 10 September 2020 - MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020. Details are as follows: Presentation Date/Time: Monday, September 14, at 4:00 p.m. EDT Online access: https://wsw.com/webcast/hcw7/maxcyte/2019107 (https://wsw.com/webcast/hcw7/maxcyte/2019107) About MaxCyte MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com (http://www.maxcyte.com) . Contacts: MaxCyte Inc. +1 301-944-1660 Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer Nominated Adviser and Joint Corporate Broker Panmure Gordon +44 (0)20 7886 2500 Emma Earl Freddy Crossley Corporate Broking Rupert Dearden Joint Corporate Broker Numis Securities Limited +44 (0)20 7260 1000 James Black Duncan Monteith Financial PR Adviser +44 (0)203 709 5700 Consilium Strategic Communications maxcyte@consilium-com Mary-Jane Elliott Chris Welsh Ashley Tapp -------------------------------------------------------------- This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy (https://www.lseg.com/privacy-and-cookie-policy) . END NRAKKCBNOBKDBCK